Journal of Medicinal Chemistry p. 4181 - 4205 (2013)
Update date:2022-08-15
Topics:
Ginman, Tobias
Viklund, Jenny
Malmstr?m, Jonas
Blid, Jan
Emond, Rikard
Forsblom, Rickard
Johansson, Anh
Kers, Annika
Lake, Fredrik
Sehgelmeble, Fernando
Sterky, Karin J.
Bergh, Margareta
Lindgren, Anders
Johansson, Patrik
Jeppsson, Fredrik
F?lting, Johanna
Gravenfors, Ylva
Rahm, Fredrik
By use of iterative design aided by predictive models for target affinity, brain permeability, and hERG activity, novel and diverse compounds based on cyclic amidine and guanidine cores were synthesized with the goal of finding BACE-1 inhibitors as a treatment for Alzheimer's disease. Since synthesis feasibility had low priority in the design of the cores, an extensive synthesis effort was needed to make the relevant compounds. Syntheses of these compounds are reported, together with physicochemical properties and structure-activity relationships based on in vitro data. Four crystal structures of diverse amidines binding in the active site are deposited and discussed. Inhibitors of BACE-1 with 3 μM to 32 nM potencies in cells are shown, together with data on in vivo brain exposure levels for four compounds. The results presented show the importance of the core structure for the profile of the final compounds.
View MoreContact:86-28-66070694 13350079802
Address:Nanyan Road,Tianfu Road sichuan ,china
Shijiazhuang Haotian Chemical Co., Ltd.
Contact:86-311-85044374
Address:293 Donggang Road
Hubei Honch Pharmaceutical Co.,Ltd
Contact:86-713-7222018
Address:Li Shizhen Pharmaceutical Industry park, Qichun County, Hubei Province,China
chengdu firsterchem Pharmaceutical Co., Ltd.
Contact:028-66825849
Address:chengdu
Contact:+1-973-357-0577
Address:10 Taft Rd.
Doi:10.1016/j.bmc.2013.03.075
(2013)Doi:10.1002/cber.19660991225
(1966)Doi:10.1016/j.tet.2013.04.044
(2013)Doi:10.1002/chem.201203644
(2013)Doi:10.1021/ja508846g
(2014)Doi:10.1016/j.tet.2013.04.129
(2013)